WOONSOCKET, R.I., Dec. 6, 2024
/PRNewswire/ -- CVS Health Corporation ("CVS Health", NYSE: CVS)
announced today the Reference Yield and Total Consideration (as
summarized in the table below) to be paid in connection with the
previously announced cash tender offer (the "Any and All Tender
Offer") for any and all of its 4.100% Senior Notes due 2025 (the
"Any and All Notes").
The Reference Yield and Total Consideration for the Any and All
Notes are summarized in the tables below:
Any and All Notes:
Title of
Notes
|
CUSIP
Number
|
Original
Issuer
|
Principal
Amount
Outstanding
|
Maturity
Date
|
UST Reference
Security
|
Bloomberg
Reference Page
|
Fixed Spread
(bps)
|
Reference
Yield
|
Total
Consideration(1)
|
4.100% Senior Notes
due 2025
|
126650CW8
|
CVS Health
Corporation
|
$950,087,000
|
3/25/2025
|
3.875% due
3/31/2025
|
FIT3
|
+25 bps
|
4.434 %
|
$998.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Per $1,000 principal
amount of Any and All Notes validly tendered at or prior to the Any
and All Expiration Date and accepted for purchase.
|
The Any and All Tender Offer is being made upon the terms and
subject to the conditions set forth in the Offer to Purchase dated
December 2, 2024 (as it may be
amended or supplemented from time to time, the "Offer to
Purchase"), which sets forth a more detailed description of the Any
and All Tender Offer. Copies of the Offer to Purchase and the form
of notice of guaranteed delivery with respect to the Any and All
Notes ("Notice of Guaranteed Delivery") are available at
www.dfking.com/cvs. The Any and All Tender Offer is open to all
registered holders (individually, a "Holder" and collectively, the
"Holders") of the Any and All Notes.
The Total Consideration for each $1,000 principal amount of the Any and All Notes
was determined in the manner described in the Offer to Purchase by
reference to the fixed spread set forth in the table above plus the
yield to maturity of the UST Reference Security set forth in the
table above on the bid-side price of such UST Reference Security as
of 11:00 a.m., New York City time, on December 6, 2024.
Any and All Notes validly tendered and not validly withdrawn, or
in respect of which a properly completed and duly executed Notice
of Guaranteed Delivery is delivered pursuant to the guaranteed
delivery procedures described in the Offer to Purchase (the
"Guaranteed Delivery Procedures"), at or prior to 5:00 p.m., New York
City time, on December 6, 2024
(such date and time, as it may be extended, the "Any and All
Expiration Date") (unless earlier terminated by CVS Health as
described in the Offer to Purchase), that are accepted for purchase
will receive the Total Consideration for the Any and All Notes.
The settlement date for the Any and All Notes validly tendered
at or prior to the Any and All Expiration Date, or validly tendered
pursuant to the Guaranteed Delivery Procedures, and accepted for
purchase is expected to be December 11,
2024, the third business day following the Any and All
Expiration Date (the "Any and All Settlement Date").
In addition to the Total Consideration for the Any and All
Notes, Holders of the Any and All Notes accepted for purchase will
receive accrued and unpaid interest ("Accrued Interest") on those
Any and All Notes from the last interest payment date with respect
to those Any and All Notes to, but not including, the Any and All
Settlement Date.
Holders who tender their Any and All Notes at or prior to
5:00 p.m., New York City time, on December 6, 2024 (such date and time, as it may
be extended, the "Any and All Withdrawal Deadline") may withdraw
such tendered Any and All Notes at any time at or prior to the Any
and All Withdrawal Deadline. Following the Any and All Withdrawal
Deadline, Holders who have tendered their Any and All Notes may not
withdraw such Any and All Notes unless CVS Health is required to
extend withdrawal rights under applicable law.
CVS Health expressly reserves the right, in its sole discretion,
subject to applicable law, to amend, extend or terminate the Any
and All Tender Offer at any time prior to the Any and All
Expiration Date. The Any and All Tender Offer is not conditioned on
any minimum principal amount of Any and All Notes being tendered
but the Any and All Tender Offer is subject to a financing
condition and certain other general conditions as described in the
Offer to Purchase.
CVS Health has retained Barclays Capital Inc. and Mizuho
Securities USA LLC to act as
Dealer Managers for the Tender Offers (as defined in the Offer to
Purchase). D.F. King & Co., Inc. has been retained to act as
the Tender and Information Agent for the Tender Offers. The Offer
to Purchase and, in connection with the Any and All Notes, the
Notice of Guaranteed Delivery may be accessed at the following
link: http://www.dfking.com/cvs. Requests for assistance relating
to the procedures for tendering Notes (as defined in the Offer to
Purchase) may be directed to the Tender and Information Agent
either by email at cvs@dfking.com, or by phone (212) 269-5550 (for
banks and brokers only) or (800) 487-4870 (for all others toll
free). Requests for assistance relating to the terms and conditions
of the Tender Offers may be directed to Barclays Capital Inc. at
(800) 438-3242 (toll free) or (212) 528-7581 (collect) or Mizuho
Securities USA LLC at (866)
271-7403 (toll-free) or (212) 205-7741. Beneficial owners may also
contact their broker, dealer, commercial bank, trust company or
other nominee for assistance.
This press release does not constitute an offer to sell or
purchase, or a solicitation of an offer to sell or purchase, or the
solicitation of tenders with respect to, the Notes. No offer,
solicitation, purchase or sale will be made in any jurisdiction in
which such an offer, solicitation, or sale would be unlawful. The
Tender Offers are being made solely pursuant to the Offer to
Purchase made available to Holders of the Notes. None of CVS
Health, the Dealer Managers, Tender and Information Agent or the
trustees with respect to the Notes, or any of their respective
affiliates, is making any recommendation as to whether or not
Holders should tender or refrain from tendering all or any portion
of their Notes in response to the Tender Offers. Holders are urged
to evaluate carefully all information in the Offer to Purchase,
consult their own investment and tax advisers and make their own
decisions whether to tender Notes in the Tender Offers, and, if so,
the principal amount of Notes to tender.
About CVS Health
CVS Health is a leading health solutions company building a
world of health around every consumer it serves and connecting care
so that it works for people wherever they are. As of September 30, 2024, the Company had more than
9,000 retail locations, more than 900 walk-in medical clinics, more
than 225 primary care medical clinics, a leading pharmacy benefits
manager with approximately 90 million plan members and expanding
specialty pharmacy solutions, and a dedicated senior pharmacy care
business serving more than 800,000 patients per year. The Company
also serves an estimated more than 36 million people through
traditional, voluntary and consumer-directed health insurance
products and related services, including expanding Medicare
Advantage offerings and a leading standalone Medicare Part D
prescription drug plan. The Company is creating new sources of
value through its integrated model allowing it to expand into
personalized, technology driven care delivery and health services,
increasing access to quality care, delivering better health
outcomes and lowering overall health care costs.
Forward-Looking Statements
This press release contains forward-looking statements. The
Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward-looking statements made by or on behalf of CVS
Health. By their nature, all forward-looking statements are not
guarantees of future performance or results and are subject to
risks and uncertainties that are difficult to predict and/or
quantify. Actual results may differ materially from those
contemplated by the forward-looking statements due to the risks and
uncertainties described in our Securities and Exchange Commission
filings, including those set forth in the Risk Factors section and
under the heading "Cautionary Statement Concerning Forward-Looking
Statements" in our most recently filed Annual Report on Form 10-K,
our Quarterly Reports on Form 10-Q for the quarterly periods ended
March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on
Form 8-K.
You are cautioned not to place undue reliance on CVS Health's
forward-looking statements. CVS Health's forward-looking statements
are and will be based upon management's then-current views and
assumptions regarding future events and operating performance, and
are applicable only as of the dates of such statements. CVS Health
does not assume any duty to update or revise forward-looking
statements, whether as a result of new information, future events,
uncertainties or otherwise.
Investor
|
Larry
McGrath
|
Media
|
Ethan Slavin
|
Contact:
|
Executive Vice
President
|
Contact:
|
860-273-6095
|
|
Chief Strategy Officer
&
|
|
Ethan.Slavin@CVSHealth.com
|
|
Chief Strategic Advisor
to the CEO
|
|
|
|
investorinfo@cvshealth.com
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cvs-health-corporation-announces-pricing-of-any-and-all-tender-offer-302325192.html
SOURCE CVS Health